Our Respiratory Data Presentations at CHEST 2020
|
Abstract Name |
Study Author |
Presentation Details |
|
Benefit–risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Marko model |
MeiLan K. Han, Daniel J. Bratton, Benjamin Hartley, Neil Barnes, Guy Brusselle, Chris Compton, Thomas C. Corbridge, Mark T. Dransfield, David M.G. Halpin, C. Elaine Jones, Paul Jones, Peter Lange, David A. Lipson, Fernando J. Martinez, Alberto Papi, Nicolas Roche, Dave Singh |
New Insights into COPD and Its Complications 10/21/2020 11:15 am - 12:15 pm
|
|
CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial |
Sule N, Fowler A, Kerstjens HA, Kerwin E, Lee L, Nathan R, Oppenheimer J, Pavord ID, Peachey G, Tabberer M, Zarankaite A, Manning ME, Millard MW, Mannino D, Hanania NA |
Updates in the Management of Severe Asthma 10/20/2020 2:30-3:30 PM
|
|
Assessment of Patient Interaction With a Dry Powder Inhaler Electronic Medication Monitor and Integrated System Within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network |
Gretchen McCreary, Barbara P. Yawn, John Linnell, Cara B. Pasquale, Elisha Malanga, Radmila Choate, David Stempel, Rahul Gondalia, Leanne Kaye, Kathryn Collison, Richard Stanford, Daniel Gratie, Benjamin Wu, Ryan Tomlinson |
|
|
Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation |
Peter M.A. Calverley, Bartolome R. Celli, Courtney Crim, Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, C. Elaine Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, Fernando J. Martinez, Andrea Morris, David E. Newby, Dave Singh, Jørgen Vestbo, Robert Wise, Julie Yates |
|
|
Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial |
Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, Benjamin Hartley, C. Elaine Jones, Ravi Kalhan, Sally Kilbride, Ken M. Kunisaki, Peter Lange, David A. Lipson, Fernando J. Martinez, Dave Singh, Robert Wise |
|
|
Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial |
Gerard J. Criner, Neil Barnes, Guy Brusselle, Chris Compton, Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, C. Elaine Jones, Mitchell Kaye, Sally Kilbride, Peter Lange, David A. Lipson, Fernando J. Martinez, Alberto Papi, Nicolas Roche, Dave Singh, Robert Wise |
|
|
Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Compared With Tiotropium Monotherapy in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis by Airflow Limitation |
Antonio Anzueto, Dany Obeid, Sandeep Bansal, Nicola Brown, Chris Compton, Thomas C. Corbridge, David Erb, Catherine Harvey, Morrys C. Kaisermann, Mitchell Kaye, David A. Lipson, Neil Martin, Chang-Qing Zhu, Alberto Papi |
|
|
Genetic Variants Do Not Predict Acute COPD Exacerbations or Treatment Response to Fluticasone furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) and its Components |
Louise K. Hosking, Astrid J. Yeo, Joshua Hoffman, Mathias N. Chiano, Dana J. Fraser, Soumitra Ghosh, David A. Lipson, Neil Martin, Lynn D. Condreay, Charles J. Cox, Pamela I. St Jean |
|
|
Cross-Sectional Survey to Assess Chronic Obstructive Pulmonary Disease (COPD) Medication use by United States (US) Physicians |
David Mannino, James Siddall, Mark Small, Adam Haq, Michael Bogart |
|
|
Cross-Sectional Survey to Assess the Burden of Nocturnal Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD) |
Xavier Soler, James Siddall, Mark Small, Michael Bogart |
|
|
Real-World Adherence to Single-Inhaler versus Multiple-Inhaler Triple Therapy among Patients with Chronic Obstructive Pulmonary Disease in a Commercially Insured US Population |
Michael Bogart, Benjamin Wu, Guillaume Germain, François Laliberté, Sean MacKnight, Young Jung, Mei Sheng Duh |
|
|
Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting β2-agonist |
Zhang S, White J, Meeraus W, Hinds D, Murali S, Tabberer M, Sansbury L, Fowler A, Lee L, Goolsby Hunter A |
|
|
Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys |
Ramesh N, Hegewald M, Maselli D, Gonzalez E, Lettieri C, Soler X, Lima R, Chang S, Marchetti N |
|
|
CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting β2-agonist therapy |
Nathan R, Boulet L-P, Kerstjens HA, Papi A, Pavord ID, Hanania NA, Oppenheimer J, Maselli DJ, Liu MC, Weinstein S, Mannino D, Peachey G, Zarankaite A, Sule N, Fowler A, Lee L, Kerwin E |
|
|
Reasons why Patients with Severe Asthma Discontinue Biologic Treatment |
Silver J, Bogart M, Molfino N, Siddall J, Small M, Hanson M, Hahn B |
|
|
Impact of Mepolizumab in Patients with Life-Threatening Asthma |
Silver J, Bogart M, Molfino N, Packnett E, McMorrow D, Wu J, Hahn B |
|
|
Medication Adherence and COPD-Related Costs among Patients with COPD Treated with Umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO) |
Slade D, Ray R, Moretz C, Germain G, Laliberte F, Shen Q, Duh MS, MacKnight S, Hahn B |
|
|
Umeclidinium/vilanterol (UMEC/VI) compared with Tiotropium (TIO) for Time-to-First Inpatient Admission among Patients with Chronic Obstructive Pulmonary Disease in a Managed Care Population |
Slade D, Ray R, Moretz C, Germain G, Laliberte F, Shen Q, Duh MS, MacKnight S, Hahn B |
|
|
Impact of Umeclidinium/vilanterol (UMEC/VI) versus Tiotropium (TIO), Fluticasone propionate/salmeterol (FP/SAL), and Budesonide/formoterol (B/F) on Time-to-First Severe Exacerbation among Patients with Chronic Obstructive Pulmonary Disease with High Comorbidities and High Costs |
Slade D, Ray R, Moretz C, Germain G, Laliberte F, Shen Q, Duh MS, MacKnight S, Hahn B |
|
